Citius Pharmaceuticals Inc (CTXR)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Leonard L. Mazur
Employees:
20
11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ 07016
(908) 967-6676

Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.

Data derived from most recent annual or quarterly report
Market Cap 126.378 Million Shares Outstanding158.967 Million Avg 30-day Volume 788.315 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.02
Price to Revenue0.0 Debt to Equity0.0 EBITDA-38.625 Million
Price to Book Value0.0 Operating Margin0.0 Enterprise Value0
Current Ratio5.057 EPS Growth0 Quick Ratio3.647
1 Yr BETA 1.1023 52-week High/Low 1.71 / 0.6 Profit Margin0.0
Operating Cash Flow Growth-6.4376 Free Cash Flow to Firm (FCFF) TTM -28.019 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score0.0

Are you looking for this stock instead?

View SEC Filings from CTXR instead.

View recent insider trading info

Funds Holding CTXR (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CTXR

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2024-02-15:
  • 8-K: filed on 2024-02-14:
  • 8-K: filed on 2024-01-23:
  • 8-K: filed on 2024-01-05:
    Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
  • 8-K: filed on 2024-01-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-10-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-25:
    Item 8.01: Other Events
  • 8-K: filed on 2023-09-15:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-09-11:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-09-08:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proposed Sales (Form 144)

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HOLUBIAK MYRON Z VICE CHAIRMAN

    • Officer
    • Director
    1,992,243 2023-10-10 1

    MCGRATH DENNIS M

    • Director
    0 2023-10-10 1

    MAZUR LEONARD L CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    • 10% Owner
    10,255,343 2023-10-10 1

    DUTIA SUREN G

    • Director
    0 2023-10-10 1

    WEBB CAROL

    • Director
    0 2023-10-10 1

    HOLUKA EUGENE MYRON

    • Director
    0 2023-10-10 1

    BARTUSHAK JAIME CHIEF FINANCIAL OFFICER

    • Officer
    60,353 2023-10-10 1

    CZUCZMAN MYRON CHIEF MEDICAL OFFICER

    • Officer
    0 2023-10-10 1

    SAFIR HOWARD

    • Director
    300,405 2022-10-04 0

    KANE WILLIAM

    • Director
    300,405 2022-10-04 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 22:15:03 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 21:45:03 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 21:15:04 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 20:45:04 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 20:15:04 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 19:45:04 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 19:15:03 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 18:45:03 UTC 0.8452 4.4648 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 18:15:05 UTC 1.2204 4.0896 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 17:45:04 UTC 1.2204 4.0896 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 17:15:04 UTC 1.2204 4.0896 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 16:45:04 UTC 1.2204 4.0896 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 16:15:04 UTC 1.2204 4.0896 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 15:45:04 UTC 1.0421 4.2679 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 15:15:04 UTC 1.0421 4.2679 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 14:45:04 UTC 0.8244 4.4956 400000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 14:15:03 UTC 0.8244 4.4956 75000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 13:45:04 UTC 0.8244 4.4956 75000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 13:15:04 UTC 0.8244 4.4956 75000
    CITIUS PHARMACEUTICALS INC CTXR 2024-02-20 12:45:03 UTC 0.8244 4.4956 75000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CTXR -16000.0 shares, $-10950.38 2023-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments